Related to this topic: Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Scleritis and Episcleritis

Episcleritis

Refers to the common and usually benign condition characterised by inflammation of the episclera, which lies between the conjunctiva and the sclera.1,2 The exact prevalence unknown (as many patients probably do not present), but it occurs most frequently in younger patients: young adult to fifth decade and is thought by some to be more common in women.The most common form is simple episcleritis which is a recurring but self-limiting inflammation affecting part (simple sectoral episcleritis) or all (simple diffuse episcleritis) of the episclera lasting 7-10 days before spontaneously resolving. Less commonly, nodular episcleritis occurs. This is more severe than simple episcleritis and takes longer to resolve. It is also much more likely to be associated with systemic disease (see below). Episcleritis does not progress to true scleritis.

Scleritis

Refers to the generally much more severe inflammation that occurs throughout the entire thickness of the sclera.3 This is rare, of the order of 0.1% of presentations in the emergency eye clinic, occurring very slightly more frequently in women and generally in an older age group than patients with episcleritis. It is classified according to which part of the sclera is affected. It may be anterior (98% of cases) or posterior (2% of cases) and there are 4 clearly recognizable groups of the anterior form:

  • Diffuse anterior - this is the most common (and benign) form characterised by widespread inflammation of the anterior sclera.
  • Nodular - there are erythematous, tender, fixed nodules which, in 20% of cases, progress onto necrotizing scleritis.
  • Necrotizing - this condition is characterised by extreme pain and marked scleral damage; it is usually associated with underlying systemic disease.
  • Scleromalacia perforans - this is also known as necrotizing anterior scleritis without inflammation and is notable for its lack of symptoms. It is most frequently associated with rheumatoid arthritis.
Presentation4,5,6
 
Episcleritis
Scleritis
Presentation
  • Acute onset
  • Mild pain / discomfort
  • Localised or diffuse red eye
  • Uni or bilateral
  • No associated ocular symptoms other than watering, vision normal.
  • Usually gradual onset
  • Severe boring eye pain often radiating to forehead, brow and jaw
  • Localised or diffuse red eye
  • Uni / bilateral (60% bilateral in anterior scleritis and 66% unilateral in posterior scleritis)
  • Associated watering, photophobia and gradual decrease in vision
  • Scleromalacia perforans may present with minimal / no symptoms.
Past history
  • Recurrent episodes common
  • May be associated with systemic disease but unusual.
  • Recurrent episodes common
  • Commonly associated with systemic disease which may be severe.
Signs relating to presentation
  • Sectoral / diffuse redness
  • Engorged episcleral vessels extending radially
  • Translucent white nodule may be present witin inflamed area
  • Vision normal.
  • Sectoral or diffuse redness
  • Scleral, episcleral and conjunctival vessels all involved
  • Sclera may take on a blue-ish tinge (best seen on gross examination in natural daylight) ± may be thin and oedematous
  • Scleromalacia perforans: may be enlarging and coalescing yellow necrotic nodules ± scleral thinning (actual perforation is rare unless intraocular pressure is elevated).
Other ocular signs
  • Corneal involvement is possible but rare
  • No intraocular inflammation.
The following may occur:
  • Corneal involvement
  • Glaucoma
  • Uveitis
  • Retinal detachment
  • Cataract formation
  • Rapid onset refractive changes.

Differentiating between episcleral and scleral vessels

Episcleral vessels can be moved with a cotton bud. If you apply phenylephrine 2.5%, they blanch (remember that this will also dilate the pupil). Scleral vessels are immobile and do not blanch.

Differential Diagnosis

Posterior scleritis has a more extensive list of differential diagnoses including:2

Episcleritis

Investigations

A simple case of episcleritis need not be investigated once a thorough history is taken and examination is carried out to rule out the unlikely possibility of an associated systemic disease (see below). If there is a suspicion, biochemical tests should be performed as guided by concern (e.g. antinuclear antibody, rheumatoid factor, serum uric acid levels etc).

Associated Diseases2,4

Management4

  • This is treated with artificial tears alone if symptoms are mild.9
  • Where the episode is more severe, a short course of intensive steroids may be required (under ophthalmologist supervision) and nodular episcleritis may respond best to oral NSAIDs.5
  • It is important to review these patients (a week after initial presentation is adequate) to ensure resolution of symptoms.
  • If the episode is severe, not resolving or if it recurs more than three times, it is appropriate to refer to the Eye Clinic.

Complications

Involvement of ocular structures is rare: there may occasionally be corneal involvement (in the form of inflammatory cell infiltrates or oedema) and recurrent attacks over a period of years may induce some degree of slight scleral thinning. Complications more commonly occur in those patients who have frequently and repeatedly need to resort to topical steroid treatment over a number of years and include cataract formation, ocular hypertension and steroid-induced glaucoma.

Prognosis1

This tends to resolve fully over 1-2 weeks but patients should be aware that episodes may recur in the same or the fellow eye.4 The treatment-related complications are the commonest cause of visual impairment in these patients (hence the need to recognise the benign nature of this disease and not to overtreat).10

Scleritis

Investigations

Every effort should be made to rule out associated ocular or systemic pathology (see below). Depending on clinical suspicion, biochemical tests (e.g. full blood count and inflammatory markers, rheumatoid screen, syphilis screen), ultrasonography of the globe, plain X rays (chest and sacroiliac joints), MRI or CT imaging (sinuses and orbits) may be indicated. The frequency of association and the severity of these associated problems mean that it has to be assumed that there is an underlying cause until proven otherwise.6 Usually, these investigations will be carried out jointly between the ophthalmologists and other relevant hospital specialists, particularly the rheumatologists.

Associated Diseases10

  • At least 50% of these patients have a underlying systemic disease and in 15% of cases, the scleritis is the first presentation of the disease.3
  • Scleritis is frequently associated with connective tissue diseases of which rheumatoid arthritis is by far the most common. Other connective tissue diseases seen are Wegener's granulomatosis, relapsing polychondritis, systemic lupus erythematosus, Reiter syndrome, polyarteritis nodosa and ankylosing spondylitis.
  • Other common associations include gout, Churg-Strauss syndrome and syphilis.
  • It may occur following ocular surgery. The aetiology is not exactly known but it tends to present as intense inflammation adjacent to the surgical site, usually within 6 months of the procedure. There is an association with the presence of underlying disease.
  • Less common associations include tuberculosis and local infections (usually spreading from a corneal ulcer) - common culprits are P. aeruginosa, Strep. pneumoniae, Staph. aureus and varicella zoster. It may also occur with Lyme disease. Fungal scleritis is very rare.
  • More unusual causes include sarcoidosis, hypertension, parasitic infestation, lymphoma8 and trauma or the presence of a foreign body.

Management

  • Management will depend on the type of scleritis and on whether there is any underlying systemic disease. These patients should all be under specialist care (usually co-managed by the ophthalmologists and rheumatologists).
  • Generally, non-necrotizing anterior scleritis will be treated with a progressive combination of oral NSAIDs (e.g. ibuprofen 400mg qds) then oral prednisolone (e.g. 80mg od) or a subconjunctival steroid injection such as triamcinolone acetonide (although this is contra-indicated in necrotizing scleritis and, some say, should be contra-indicated in scleritis altogether4) ± immunosuppressive therapy such as methotrexate. It may take several weeks to adjust the treatment to produce a satisfactory result.
  • Necrotizing anterior scleritis is managed with systemic steroids and immunosuppressive therapies and may need surgical intervention if perforation is impending.10
  • Treatment has very limited effect in scleromalacia perforans2,6 but abundant lubrication may also be added to the regimen.
  • Management of posterior scleritis is a little more controversial: young patients usually respond well to oral NSAIDs2 but elderly patients with associated disease are managed as with anterior non-necrotizing scleritis.
  • All patients with scleritis should have any underlying disease addressed.

Complications10

  • Scleral thinning
  • Ischaemia of the anterior segment of the globe
  • Raised intraocular pressure
  • Retinal detachment
  • Uveitis
  • Cataract
  • Phthisis (globe atrophy)

Prognosis

Generally, when scleritis originates from a systemic disorder, its course follows that of the underlying problem.3 However, anterior necrotizing scleritis with inflammation is the most severe and distressing form of the disease. Most patients have an associated vascular disease. Visual prognosis is poor and there is a mortality rate related to the underlying condition of ~ 25% within 5 years of the onset of scleritis.2 Posterior scleritis in patients over 50 is associated with an increased risk of harbouring systemic disease and suffering visual loss.

Prevention

There are no clear cut prevention measures other than the rigorous control of the progression of any underlying disease and early treatment of the scleritis to minimise the risk of visual loss.


Document References
  1. Roy Sr H; eMedicine: Episcleritis. Last updated October 2006.
  2. Kanski J. Clinical Ophthalmology, A Systematic Approach, 5th Ed, 2003, Butterworth Heinemann.
  3. Naradzay JFX, Adler J; eMedicine: Scleritis. Last updated February 2006.
  4. Kunimoto DY, Kanitkar KD, Makar MS; The Wills Eye Manual, 4th Edition, 2004, Lippincott, Williams and Wilkins.
  5. Handbook of Ocular Disease Mangement; Episcleritis.
  6. Handbook of Ocular Disease Management; Scleritis.
  7. Gungor K, Bekir NA, Namiduru M; Recurrent episcleritis associated with brucellosis. Acta Ophthalmol Scand. 2001 Feb;79(1):76-8. [abstract]
  8. Thakker MM, Perez VL, Moulin A, et al; Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma. Ophthalmology. 2003 May;110(5):1057-60. [abstract]
  9. Williams CP, Browning AC, Sleep TJ, et al; A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. Eye. 2005 Jul;19(7):739-42. [abstract]
  10. McCluskey P: Scleritis. Fundamentals of Ophthalmology Series, BMJ books, 2001.
Acknowledgements EMIS is grateful to Dr Olivia Scott for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2755
Document Version: 21
DocRef: bgp1976
Last Updated: 6 Dec 2006
Review Date: 5 Dec 2008






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page